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Precis: Women newly diagnosed with breast cancer turn to others, including spouses, children 
and friends to support them in their treatment decision making. These informal supporters are 
actively involved in the decision process and involving more supporters was associated with 
more deliberative treatment decisions. 
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ABSTRACT 
 
 
Background: Little is known about the size and characteristics of the decision support networks 
of women newly diagnosed with breast cancer and whether their involvement improves breast 
cancer treatment decisions.  
 
Methods: A population-based sample of patients newly diagnosed with breast cancer in 2014-
15 as reported to the Georgia and Los Angeles SEER registries were surveyed approximately 7 
months after diagnosis (N = 2,502, 68% response rate). Network size was estimated by asking 
women to list up to 3 of the most important decision support people (DSP) who helped them 
with locoregional therapy decisions. Decision deliberation was measured using 4-items 
assessing degree to which patients thought through the decision, with higher scores reflecting 
more deliberative breast cancer treatment decisions. We compared the size of the network (0-3 
or more) across patient-level characteristics and estimated the adjusted mean deliberation 
scores across levels of network size using multivariable linear regression.  
 
Results: Of the 2,502 women included in this analysis, 51% reported having 3 or more DSPs, 
20% reported 2, 18% reported 1, and 11% reported not having any DSPs. Married/partnered 
women, those younger than 45 years old, and black women were all more likely to report larger 
network sizes (all p<0.001). Larger support networks were associated with more deliberative 
surgical treatment decisions (p <0.001).  
 
Conclusions: Most women engaged multiple DSPs in their treatment decision making, and 
involving more DSPs was associated with more deliberative treatment decisions. Future 
initiatives to improve treatment decision making among breast cancer patients should 
acknowledge and engage informal DSPs.  
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INTRODUCTION 
 
Patient centered care supports engaging patients to make decisions that are both informed and 
values/preference-concordant. This can be challenging in breast cancer because of the 
complexity and number of decisions faced by newly diagnosed patients. To help facilitate 
decision making, women often seek guidance from multiple source, including family and 
friends.1-6 While many studies have examined the role family and friends play in caring for 
patients with cancer,7-9 there is surprisingly little research on the contribution of informal 
supporters to the decision-making process specifically. Indeed, most women diagnosed with 
breast cancer have an informal support person in the room with them during the first encounter 
with a surgeon. Our prior work suggests that partners positively appraised their participation in 
these treatment decisions,10 and a recent study found both patients and caregivers felt family 
involvement was helpful in their cancer treatment decision making.11 But, who patients involve in 
these decisions, the extent to which they are involved and whether or not their participation 
influences the quality of these treatment decisions remains largely unknown. 
 
In addition, very little is known about the decision support networks themselves and how they 
may vary for different patient groups. For instance, prior research suggests that the involvement 
and influence of informal decision support persons (DSPs) may vary by race/ethnicity,3, 10 but 
much of the research has been limited by small sample sizes with insufficient racial/ethnic 
diversity, and by the inclusion of only spouses/partners.4-6 While clinicians have long been 
recommending that patients bring someone with them to their appointments, clinicians may 
benefit from a better understanding of the size and characteristics of the networks that patients 
rely on during their decision making. Such understanding may help clinicians to better 
incorporate DSPs into treatment discussions and would help guide the development of decision 
tools that include patients’ informal DSPs, with the goal of improving patient-centered care. In 
particular, establishing whether informal decision support networks contribute to greater 
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deliberation over treatment options would allow clinicians to provide more evidence based 
recommendations that patients utilize their network of informal supporters when making their 
breast cancer treatment decisions.  
 
To fill this gap in research on the process of breast cancer treatment decision making, we 
conducted a study to characterize the size and variation of informal decision support networks 
for women newly diagnosed with early-stage breast cancer. We further sought to determine 
whether network size was associated with patient characteristics, and patients’ appraisal of their 
decision making process. 
 
METHODS 
Study population 
The Individualized Cancer Care (iCanCare) Study is a large, population-based survey study of 
women with breast cancer. We identified and accrued 3930 women, ages 20-79 with newly 
diagnosed, early-stage breast cancer (stages 0-II) as reported to the SEER registries of Georgia 
and Los Angeles County in 2014-2015. Patients were ineligible if they had stage III or IV 
disease, had tumors larger than 5cm, or could not complete a questionnaire in English or 
Spanish (N= 258). Of the remaining 3,672 eligible women who were mailed surveys, 2,502 
completed the survey (68% response rate) and are included in this analysis.  
 
Patients were identified via rapid case ascertainment from surgical pathology reports. Surveys 
were mailed approximately 2 months after surgery (median time from diagnosis to survey 
completion was 7 months). We provided a $20 cash incentive and, as done in prior work,12-14 
used a modified Dillman approach to encourage patient recruitment.15 This approach allows for 
a flexible mode of respondent follow-up, which included post-card reminders and phone 
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reminders with the option to complete the survey during a phone interview in either Spanish or 
English. All materials were sent in English and Spanish to those with Spanish surnames.3, 13 
Survey responses were then merged with clinical data provided by the SEER registries. The 
study was approved by the University of Michigan Institutional Review Board and the state and 
institutional IRBs of the SEER registries.  
 
Measures 
Questionnaire content was developed based on a conceptual framework which hypothesized 
variability in the size and influence of decision support networks across patient-level 
characteristics.1-3 We utilized standard techniques to assess content validity, including expert 
reviews, cognitive pretesting, and pilot studies in selected clinic populations. Respondents were 
queried about the number, influence and importance of decision support persons using adapted 
measures developed and validated to identify disease management supports for patients with 
chronic diseases.16, 17 (See Supplementary Material for measures.) 
 
Measuring decision support networks: To our knowledge, this is the first study to ask 
patients to report about specific individuals involved in their cancer treatment decision making. 
We employed a unique methodology where patients were asked: (1) to indicate up to three 
specific decision support individuals (using initials only to avoid identification), (2) to indicate 
each person’s relationship to them (e.g., partner, daughter, friend), and (3) to rate the 
importance of, and satisfaction with, each person’s involvement in treatment decision making. 
 
Size of decision support network: The decision support network size was determined by 
assessing the number of individuals indicated by each patient, ranging from 0 to 3 or more. 
While rare (n=256, 10.2%), respondents who did not answer the decision support questions 
entirely were categorized as having a decision support network size of zero. This categorization 
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was based on prior work and responses to other questions that services to support the 
justification that patients likely did not answer because they did not have a person to name. 
However, to confirm our findings, we also performed the analyses with these respondents 
excluded, which yielded very similar results.  
 
Patient satisfaction with and importance of DSPs: For each individual listed, respondents 
reported on how important the opinion of each DSP was in treatment decision making, and how 
satisfied they were with the level of involvement (each on 5 pt. scale from “not at all” to “very”). 
Overall mean scores (across all DSPs reported by each patient) were then estimated for both 
importance and satisfaction and categorized into high (score of 4 or greater) vs. low/moderate 
(score less than 4). We chose this cut off based on prior research (Hawley JCNI, Lillie) and our 
desire to assess the highest levels of patient-reported involvement and satisfaction.  
 
Patient-reported network involvement: As we have done in prior studies (Hawley JNCI, Janz 
Supportive Cancer Care), respondents were also asked how often their DSP(s) attended their 
appointments, took notes during appointments, talked to them about their treatment options, 
and shared information with them from other sources about their treatment options (5 pt. scales 
from “not at all” to “often”). Overall mean scores were then estimated for each item and 
categorized into often/always (score of 4 or greater) vs. never/rarely (score less than 4).  
 
Patient appraisal of decision making: We employed a measure of “treatment decision 
deliberation”, using a 5-item scale derived from measures of public deliberation adapted for 
cancer treatment-related decisions.18-20 Items assessed the extent to which a patient weighed 
the pros and cons, talked to other family members and friends, talked to other breast cancer 
patients, thought through, and spent time thinking about the decision (on 5-pt Likert-type scales 
from “not at all” to “very much”). An overall deliberation score was created using the mean of the 
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responses to the five items (range 1-5) (Cronbach alpha =0.85), with higher scores representing 
more deliberation.  
 
Patient Characteristics 
Survey items assessed demographics including age, educational attainment (high school 
graduate or less, some college or college degree or more), insurance status (private, 
Medicaid/Medicare/VA, or none/missing), and number of comorbid health conditions (0, 1 or 
more). Level of acculturation among Latinas was assessed using the Short Acculturation Scale 
for Hispanics (SASH), as done in our prior studies.21 We also asked patients to report their 
treatment, as done in prior work,12 including primary surgical treatment modality (lumpectomy, 
unilateral mastectomy, bilateral mastectomy), receipt of chemotherapy (yes/no) and endocrine 
therapy (yes/no). Breast cancer stage (0, I, II) was obtained from the SEER record. 
 
Statistical Analyses 
All statistical analyses incorporated weights to account for differential probabilities of sample 
selection across patient subgroups and non-response. Weighting assures that sample 
distributions resemble those of the target population and reduces the potential bias due to non-
response.22 The overall distributions of network characteristics (size, relationship), DSP 
involvement, and patient-reported satisfaction with and influence of the DSP were estimated. 
The distributions of network size across levels of patient demographic and clinical 
characteristics were compared using Rao-scott Chi-square tests. Because of the anticipated 
inherent association between network size and marital status, we then estimated the 
associations between patient factors (age, race/acculturation) and network size, stratified by 
marital status and compared them using Rao-scott Chi-square tests. Multivariable linear 
regression was used to estimate the adjusted mean deliberation scores for each level of 
network size, adjusting for age, race/acculturation, insurance, partner status, comorbidity, 
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surgical treatment and stage.  All analyses were performed using SAS 9.4 (Cary, NC), used 
two-sided tests, and p-values <0.05 were considered statistically significant.  
  
 
RESULTS 
Network Size  
Table 1 displays the characteristics of the sample of 2,502 women both overall and by level of 
informal decision support network size. More than half of the women (51%) listed three DSPs 
during their treatment decision making, 20% listed two people, 19% listed one person and 10% 
had a network size of zero. Network size decreased with increasing age (p<0.001). Variation in 
network size also existed across race/acculturation (p<0.001). Both African American and 
Latina women reported larger network sizes compared to white women, as 58.3% of African 
American women and 52.3% and 56.4% of high and low acculturated Latina women reported a 
network size of 3 or more, compared to 48% of white women (p<0.001). As expected, marital 
status was positively associated with network size: Among women who were partnered/married, 
51.6% reported a network size of 3 or greater compared to 49.3% of women who were not 
married or partnered (p<0.001). (Table 1) 
 
Figure 1 displays the size of the decision support network across age and race, stratified by 
partner status. Very little heterogeneity was seen in the association between age and network 
size across partner status. Among both partnered and not partnered women, a greater 
proportion of younger women reported a larger network size compared to older women, albeit 
these associations did not reach statistical significance (not partnered p=0.06; partnered 
p=0.10) (Figures 1A-B).  
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The association between race/acculturation and network size varied noticeably across partner 
status. Among women who were partnered, race/acculturation was significantly associated with 
network size (p<0.001), as 63% of black women, 56% of high and 60% of low acculturated 
Latina women and 48% of white women reported a network size of 3 or more, (Figure 1D). This 
association, however, was mitigated among women who were not partnered (p=0.80). (Figure 
1C)  
 
Characteristics of Networks  
Table 2 displays the distributions of the size, relationship and involvement of the decision 
support networks both overall and stratified by marital status. Of the DSPs that the respondents 
identified, overall most (31.2%) were children, followed by partners/spouses (21.2%), 18.8% 
friends/other (18.8%), siblings (11.3%), other family members (7.4%), and parents (6.1%). 
Partnered/married women most often reported their partner as their main DSP (37.9%), 
whereas not partnered/unmarried women most often reported children as their main DSP 
(38.4%). In addition, women who were not partnered or married more often reported siblings as 
their DSP (15.5%) or friends (22.3%) as compared to partnered/married women (p<0.001).  
 
Satisfaction with and Involvement of Networks  
Overall, women reported that their DSPs participated in key activities related to their decision 
making. The majority of women reported that their DSPs often/always talked to them about their 
treatment options (74.2%) and frequently attended their appointments (73.3%), and these 
activities were more common among partnered women when compared to non-partnered 
women (both p<0.001). However, women overall were less likely to report that their DSPs had 
taken notes (50.5%), or shared treatment information with them from other sources (56.8%).  
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The majority of women were highly satisfied with their DSP being involved in their treatment 
decisions (76.5%) and over two-thirds (68.6%) felt their DSP was very important in their 
treatment decision making. However, both satisfaction and importance were significantly 
different across partner status; Partnered women were more likely to be highly satisfied and 
perceive their DSP to be of high importance compared to non-partnered women (both p<0.001). 
In addition, younger women, Black and Latina women and those with less education were more 
likely to perceive that their DSP was highly important (results not shown). (Table 2) 
 
Association with Decision Deliberation 
There was a significant association between network size and treatment deliberation scores, 
after adjustment for age, race, insurance, partner status, comorbidity, SEER stage, and surgical 
treatment. Mean treatment deliberation scores were lowest among women who had a network 
size of zero (mean deliberation score=3.04), and highest among women with a network size of 3 
or more (mean deliberation score=3.59) (p<0.001). (Figure 2)  
 
 
DISCUSSION 
In this study that used a unique methodology to understand how family and friends contribute to 
the treatment decisions made by breast cancer patients, most reported having a large informal 
decision support network and also felt their supporters were both important and influential. 
Women with larger networks also reported more deliberative surgical treatment decisions, a 
promising outcome particularly at a time where there is concern that patients are rushing into 
making breast cancer treatment decisions.23-25 Our results suggest that engaging DSPs in the 
treatment decision process may be an important mechanism for slowing these decisions down, 
potentially allowing patients to more deeply consider them. 
 
Page 12 of 28Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
13 
 
Our findings confirm prior work showing that most women do not make their breast cancer 
treatment decisions on their own, and instead heavily involve other support people in these 
emotional and difficult decisions.1-6, 11, 26 Our study extends this work by revealing that the 
decision support network for newly diagnosed breast cancer patients is larger than previously 
understood. In fact, we found that the majority of breast cancer patients reported having large 
networks, defined in this study as having 3 or more informal DSPs, and we further discovered 
that these supporters often included family members and friends beyond just their partners or 
spouses. In our large sample of non-married/partnered women—not previously well represented 
in studies of informal support—we found that children and friends were commonly considered 
key DSPs. Yet, we also showed that even among married/partnered women, children and 
friends played an important DSP role. These results underscore the need recognize the 
significant impact of informal DSPs—partners, children, friends—in the treatment decision 
making process and choices of breast cancer patients. 
 
As expected, we did find some variation in network size in different patient subgroups, with  
younger and minority women indicating they had larger decision support networks.  
Prior research suggests that racial/ethnic minorities are more likely to rely on family for 
emotional/spiritual support and caregiving functions,1, 27 but this is one of the first studies to 
show that this is also the case for decision support specifically. In addition, even though African 
American women tended to be partnered/married at lower rates in our sample, they still had 
large networks that supported their decision making. Likewise, Latina women with low 
acculturation also reported larger network sizes, underscoring that for minorities with potential 
language barriers that make communication with their physicians more challenging,13, 14 the 
inclusion of DSPs offer another opportunity to educate patients about their treatment options. 
Efforts by clinicians to engage with the DSPs of minority women and to recognize that women 
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often have DSPs beyond their spouses or partners may be beneficial in ensuring information is 
communicated in a culturally sensitive and understandable manner. 
 
Our results also suggest that informal DSPs are actively engaged with patients throughout their 
treatment decision making and that there may be a real benefit to having a decision support 
network during this process. In addition to there being a strong association between the number 
of supporters and more treatment deliberation, the majority of women in this sample also 
reported they were highly satisfied with their DSPs’ level of involvement and felt they played an 
important role in their treatment decision making. Prior work from Shin and colleagues also 
suggests that patients and caregivers value family involvement in cancer treatment decision 
making.11, 26 Our findings that the majority of women also reported having DSPs who often 
attended their appointments, took notes, discussed their treatment options and shared 
information with them from other sources suggests that support networks are also highly 
involved throughout the decision process. This involvement may be particularly helpful around 
the time of diagnosis when patients are struggling to absorb information while simultaneously 
coping with their cancer diagnosis. It also suggests that they may be a benefit to addressing 
decision supporters within structured tools, or decision aids, designed to improve treatment 
decision making. While there are many decision aids available for breast cancer patients, none 
of them currently address the role of informal supporters in helping women navigate these 
treatment decisions and none directly engage supporters. Therefore, future decision aids and 
other interventions focused on improving breast cancer decision making should address the role 
of the DSP more directly.  
 
Taken together, the results from this study suggest that the involvement of informal supporters 
in breast cancer treatment decisions provides an opportunity for clinicians to better incorporate 
them into these treatment decisions. Clinicians should be aware that women who include more 
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informal decisions supporters in their treatment decisions may take longer to fully weigh 
treatment options and require additional time to make value- and preference-concordant 
decisions. Therefore, clinicians might discuss with patients the availability of informal DSPs and 
encourage their involvement early in the treatment consultation process. Clinicians should also 
anticipate delivering treatment information to at least one person beyond the patient and should 
also realize that among married/partnered women, the spouse/partner is not necessarily the 
family member that the patient considers to be her informal decision support person. Equally 
important, however, is recognizing that women who do not have an informal support person—as 
reported by 10% of patients in our sample, including a small proportion of women who were 
married/partnered, may be vulnerable to lower quality treatment decisions and may thus require 
additional decisional support.  
 
While this study was a large population-based survey in a diverse sample with a high survey 
response rate, there are some potential limitations that merit consideration. This was a cross-
sectional survey, and therefore inferences regarding causality are limited. We relied on patient 
report of their DSPs, including their influence and importance, which may be subject to recall 
bias. However, we captured this information on average only 2 months after surgery, thus 
minimizing the potential for this bias. We only asked women to identify up to three DSPs, and 
thus our estimates about the size of the decision support networks are most likely conservative. 
Finally, this sample only included women treated for breast cancer in Georgia and Los Angeles, 
and thus the generalizability of our findings may be limited.    
 
 
CONCLUSIONS 
Although prior research on breast cancer treatment decision making has tended to focus on the 
patient, our study is one of the largest to date that highlights the need to consider patients in the 
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context of their informal decision support networks. Patients turn to others, including spouses, 
children, and friends, to help support them in these difficult and complicated decisions and these 
others are actively involved in helping patients make these decisions. The effectiveness of 
future initiatives to improve treatment decision making among breast cancer patients, including 
decision support tools, may be limited if they do not acknowledge and engage informal decision 
supporters.  
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Figure Legends 
Figure 1: Distribution of network size by age (A/B), race (C/D), stratified by partner 
status 
Figure 1A: Network size by age among non-partnered women (p=0.06) 
Figure 1B: Network Size by age among partnered women (p=0.09) 
Figure 1C: Network size by race/acculturation among non-partnered women (p=0.80) 
Figure 1D: The distribution of network size by race/acculturation among partnered 
women (p<0.001) 
 
Figure 2: Adjusted mean deliberation scores by network size (p<0.001). Adjusted for 
age, race, insurance, education, partner status, comorbidity, SEER stage, and surgical 
treatment. 
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Table 1: Distribution (weighted %) of demographic and clinical characteristics by 
decision supporter network size 
 
  Decision Supporter Network Size 
(weighted %) 
 
Patient-level Factors Overall 
N=2502 
0 
N=256 
 
1 
N=460 
2 
N=501 
3 
N=1285 
 
p-value* 
Age        
<45 8.2 3.3 14.9 20.9 60.9 0.001 
45-54 20.4 10.7 16.9 21.9 50.6  
55-64 31.3 8.5 20.3 18.2 53.0  
>65 40.1 12.5 19.8 20.9 46.9  
Race/acculturation       
White 54.2 9.5 21.4 21.0 48.0 <0.001 
Black 18.0 9.4 15.3 17.0 58.3  
Latina, high acculturation 7.9 12.8 14.9 19.9 52.4  
Latina, low acculturation 7.7 10.2 15.0 18.4 56.4  
Asian 9.8 9.2 19.1 24.5 47.2  
Other/unknown/missing 2.5 25.0 15.5 17.8 41.6  
Education        
High school graduate or 
less 
29.9 10.7 18.0 18.6 52.8 0.26 
Some College 29.8 8.6 18.2 20.3 52.8  
College graduate or more 40.3 9.3 20.8 21.9 48.0  
Insurance        
None or Missing 20.2 15.7 14.1 16.8 53.4 <.0001 
Medicaid, Medicare or VA 35.2 9.7 18.6 21.0 50.7  
Private or Other 44.6 8.0 21.5 21.2 49.4  
Partner/marital status       
Not partnered/Married 38.9 15.5 15.9 19.3 49.3 <.0001 
Partnered/Married 61.0 6.2 21.1 21.2 51.6  
Comorbidity       
0 67.8 10.4 19.8 20.6 49.2 0.24 
1+ 32.2 9.6 17.1 19.6 56.7  
SEER Stage       
0 24.9 11.7 20.4 18.6 49.3 0.26 
I 50.1 9.3 19.7 20.2 50.8  
II 24.0 10.8 15.5 21.4 52.4  
Surgical Treatment       
Lumpectomy 64.6 10.5 20.4 19.9 49.1 0.11 
Unilateral Mastectomy 17.4 9.3 14.9 19.9 55.9  
Bilateral Mastectomy 18.0 8.1 17.5 21.1 53.3  
*P-values from Rao-Scott chi-square tests for association  
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Table 2: Network Characteristics and DSP Involvement in Treatment Decision 
Making (N=2502), stratified by Partner Status 
 
* N is unweighted and does not add up to 2502 due to missingness. 
**Relationships were categorized for all reported DSPs for each patient 
Network Characteristics Overall 
N=2502* 
Not Partnered 
N=961 
Partnered 
N=1496  
p-values 
 weighted % weighted % weighted %  
Network Size (n=2457) 
0 
1 
2 
3+ 
 
9.8 
19.0 
20.5 
50.7 
 
15.5 
15.9 
19.3 
49.3 
 
6.2 
21.1 
21.2 
51.6 
<0.001 
DSP Relationship to Patient** 
Partner/Spouse 
Children 
Siblings 
Parent 
Other Family Members 
Friends/Other 
Multiple 
 
21.2 
31.2 
11.3 
6.1 
7.4 
18.8 
4.0 
 
2.3 
38.4 
15.5 
6.4 
11.0 
22.3 
4.1 
 
37.9 
27.0 
8.0 
5.5 
4.6 
13.5 
3.6 
<0.001 
DSP Involvement     
Attended Appointments (n=2394) 
Never/rarely/often  
Very Often/always   
 
26.7  
73.3 
 
37.7 
62.3 
 
19.8 
80.2 
<0.001 
Took Notes during Appointments 
(n=2377) 
Never/rarely/often  
Very Often/always   
 
 
49.5 
50.5  
 
 
51.9 
48.1 
 
 
47.9 
52.1 
 
0.076 
Talked with them about Treatment 
(n=2364)  
Options 
Never/rarely/often   
Very Often/always  
 
 
 
25.8 
74.2 
 
 
 
32.9 
67.1 
 
 
 
21.3 
78.7 
<0.001 
Shared information about treatment 
from other sources (n=2380) 
Never/rarely/often  
Very Often/always  
 
 
43.2 
56.8  
 
 
44.1 
55.9 
 
 
42.6 
57.4 
0.49 
Patient-reported DSP Measures     
Patient-reported Satisfaction with 
DSP (n=2457) 
Low/Moderate (<4) 
High (≥4) 
 
 
23.5  
76.5 
 
 
30.4 
69.6 
 
 
19.0 
81.0 
<0.001 
Patient-reported DSP Importance 
(n=2457) 
Low/Moderate (<4) 
High (≥4) 
 
 
31.4 
68.6  
 
 
38.7 
61.3 
 
 
26.8 
73.2 
<0.001 
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Figure 1: Distribution of network size by age (A/B), race (C/D), stratified by partner status  
Figure 1A: Network size by age among non-partnered women (p=0.06)  
Figure 1B: Network Size by age among partnered women (p=0.09)  
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Figure 1: Distribution of network size by age (A/B), race (C/D), stratified by partner status  
Figure 1C: Network size by race/acculturation among non-partnered women (p=0.80)  
Figure 1D: The distribution of network size by race/acculturation among partnered women (p<0.001)  
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Figure 2: Adjusted mean deliberation scores by network size (p<0.001). Adjusted for age, race, insurance, 
education, partner status, comorbidity, SEER stage, and surgical treatment.  
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Supplementary Material: Measures from Patient Survey 
Section G:  Support from Others  
The information below will allow us to better understand how family and friends help breast cancer patients 
with treatment decisions and will provide us with ideas on how to offer more support in the future. 
G1. When decisions were being made about your treatments for your breast cancer, who were the most 
important people who helped you with those decisions?  
Please print the initials 
of up to 3 people who 
were involved in your 
decision making and 
their relationship to you 
(e.g. family, friend, 
other) 
How important was this 
person’s opinion in your 
treatment decision making?   
Please circle ONE option 
where 1 is not at all 
important and 5 is very 
important. 
How satisfied were you with 
how involved this person 
was? 
Please circle ONE option 
where 1 is not at all 
satisfied and 5 is very 
satisfied. 
Which treatment 
decision(s) was this 
person involved in? 
Please mark ALL 
that apply. 
EXAMPLE   
L.W., Daughter 
EXAMPLE 
1         2        3       4       5 
Not at all                                      Very 
Important                            Important 
EXAMPLE 
1         2        3       4       5 
Not at all                                      Very 
Satisfied                               Satisfied 
EXAMPLE 
     Which surgery to have    
     Whether or not to 
have radiation therapy   
     Whether or not to 
have chemotherapy 
1. 
1       2       3       4       5 1       2       3       4       5 
     
     Which surgery to have    
     Whether or not to 
have radiation therapy   
     Whether or not to 
have chemotherapy 
2. 
1       2       3       4       5 1       2       3       4       5 
     
     Which surgery to have    
     Whether or not to 
have radiation therapy   
     Whether or not to 
have chemotherapy 
3. 
1       2       3       4       5 1       2       3       4       5 
     
     Which surgery to have    
     Whether or not to 
have radiation therapy   
     Whether or not to 
have chemotherapy 
 
 
 
 
 
 
 
3 3 
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G2.  Thinking about the family and friends who helped you with your treatment decisions, how often did one of 
these people* 
 Never Rarely   Sometimes   Often Very often 
a. Attend doctor appointments with you where decisions 
about your treatment plan were discussed  
     
b. Take notes for you during a doctor’s appointment    
 
 
c. Talk to you about your treatment options    
 
 
d. Share information with you from other sources about 
your treatment options (for example, from the internet 
or from talking with others)  
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